ACM
NGNE icon

ACT Capital Management’s Neurogene NGNE Stock Holding History

ACT Capital Management’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$127K Hold
9,950
– – 0.18% 46
2022
Q2 		$205K Hold
9,950
– – 0.29% 41
2022
Q1 		$374K Sell
9,950
-675
-6% -$39.4K 0.4% 38
2021
Q4 		$1.02M Sell
10,625
-1,325
-11% -$161K 0.74% 29
2021
Q3 		$1.73M Hold
11,950
– – 0.9% 25
2021
Q2 		$2.21M Buy
+11,950
New +$2.64M 1.13% 18

Other funds holding NGNE

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

ACT Capital Management's NGNE Position: Q3 2022 in Review

ACT Capital Management held its Neurogene (NGNE) position steady in Q3 2022 at 9,950 shares worth $127K. The position accounts for 0.18% of the portfolio, ranked #46.

ACT Capital Management first reported a position in NGNE in Q2 2021 and has held it in 6 quarters since. The position peaked at $2.21M in Q2 2021. 52 funds tracked by Wall St. Rank hold NGNE as of Q3 2022.

  • ACT Capital Management held 9,950 shares of Neurogene worth $127K as of Q3 2022.
  • ACT Capital Management left its Neurogene share count unchanged in Q3 2022.
  • Neurogene made up 0.18% of ACT Capital Management's portfolio in Q3 2022, its #46 holding.
  • ACT Capital Management first reported a position in Neurogene in Q2 2021 and has held it in 6 quarters since.
  • ACT Capital Management's Neurogene position peaked at $2.21M in Q2 2021.
  • 52 funds tracked by Wall St. Rank held Neurogene as of Q3 2022.

Based on ACT Capital Management's 13F filing for Q3 2022, filed 3 Nov 2022.